Drug Trial Radar · NCT04729114
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
174
Planned (sponsor's estimate)
Start
Jun 14, 2021
Primary completion
May 31, 2029
Study completion May 31, 2029
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jan 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their cancer has come back after previous cancer treatment, or the previous cancer treatment they had didn't work. The main aims of the study are: * to check the safety of PRL-02 depot given with and without another medicine called enzalutamide. * to check if the men can tolerate PRL-02 depot given with or without enzalutamide. * to find a suitable dose of PRL-02 depot. This study will be in 2 parts. In the first part, different small groups of men will receive lower to higher doses of PRL-02 depot together with other medicines. In the second part of the study, men who have previously taken a hormone therapy called abiraterone acetate or have previously taken 1 specific hormone therapy as part of their prostate cancer treatment can take part. Men in both parts of the study will receive injections of PRL-02 depot into a muscle once every 12 weeks. They will also take dexamethasone or prednisone, or enzalutamide once a day. The other medicines they take depend on which group and which part of the study they are in. During the study, the men will visit the clinic several times for health checks and scans. After the final visit, men whose cancer has not become worse will continue to have health checks and scans every few months.
Conditions
- Prostate Cancer
- Metastatic Castration Resistant Prostate Cancer
- Metastatic Castration-sensitive Prostate Cancer
Interventions
PRL-02 injectionDrug
abiraterone decanoate for intramuscular injection
prednisoneDrug
Oral dose
dexamethasoneDrug
Oral dose
enzalutamideDrug
Oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days
- Number of Participants with Adverse Events (AEs)Time frame: Up to 4 years
- Number of Participants with Serious Adverse Events (SAEs)Time frame: Up to 4 years
- Number of Participants with laboratory value abnormalities and/or AEsTime frame: Up to 4 years
- Number of Participants with electrocardiogram (ECG) abnormalities and/or AEsTime frame: Up to 4 years
- Number of Participants with vital sign abnormalities and/or AEsTime frame: Up to 4 years
- Number of Participants with physical exam abnormalities and/or AEsTime frame: Up to 4 years
- Number of Participants with Eastern Cooperative Oncology Group (ECOG) performance status scoreTime frame: Up to 4 years
- Testosterone Suppression of Participants as Assessed by Testosterone LevelsTime frame: Up to 4 years
Locations
25 sites in 2 countries. Site status is shown where the registry gives one.
Arizona Urology Specialists
Tucson, Arizona · Withdrawn
Los Angeles Cancer Network
Anaheim, California · Recruiting
Providence Medical Group Oncology Santa Rosa
Santa Rosa, California · Recruiting
Florida Urology Partners
Tampa, Florida · Withdrawn
Fort Wayne Medical Oncology and Hematology, Inc.
Fort Wayne, Indiana · Withdrawn
First Urology
Jeffersonville, Indiana · Recruiting
Wichita Urology Group
Wichita, Kansas · Recruiting
National Cancer Institute
Bethesda, Maryland · Withdrawn
Chesapeake Urology
Towson, Maryland · Recruiting
XCancer Center Omaha/Urology Cancer Center
Omaha, Nebraska · Completed
Garden Sate Urology
Morristown, New Jersey · Withdrawn
New Mexico Oncology Hematology Consultants Ltd
Albuquerque, New Mexico · Recruiting
Duke Cancer Center
Durham, North Carolina · Recruiting
Helios Clinical Research, LLC
Middleburg Heights, Ohio · Withdrawn
Toledo Clinical Cancer Center
Toledo, Ohio · Withdrawn
MidLantic Urology
Bala-Cynwyd, Pennsylvania · Recruiting
Carolina Urologic Research Center
Myrtle Beach, South Carolina · Recruiting
Urology Associates PC
Nashville, Tennessee · Recruiting
Urology Clinics of North Texas
Dallas, Texas · Recruiting
Houston Metro Urology
Houston, Texas · Recruiting
Oncology Consultants
Houston, Texas · Withdrawn
Urology San Antonio
San Antonio, Texas · Withdrawn
University of Virginia Cancer Center
Charlottesville, Virginia · Recruiting
Northwest Medical Specialties
Tacoma, Washington · Recruiting
Pan American Center for Oncology Trials, LLC
San Juan, Rio Piedras, Puerto Rico · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.